David K Tumusiime1, Emmanuel Musabeyezu2, Eugene Mutimurah3, Donald R Hoover4, Qiuhu Shi5, Emmanuel Rudakemwa6, Victorien Ndacyayisenga7, Jean Claude Dusingize8, Jean D'Amour Sinayobye9, Aimee Stewart9, Francois W D Venter10, Kathryn Anastos11. 1. University of the Witwatersrand, Johannesburg and Kigali Health Institute, Kigali, Rwanda; dtumusime@khi.ac.rw. 2. King Faisal Hospital Kigali (KFH, K) Kigali Rwanda; emusabeyezu@gmail.com. 3. Regional Alliance for Sustainable Development (RASD), Kigali Rwanda, eugene.mutimura@gmail.com. 4. The State University of New Jersey, New Brunswick, NJ USA drhoover@stat.rutgers.edu. 5. School of Health Sciences and Practice, New York Medical College, NY, USA, qshi@data2solutions.com. 6. King Faisal Hospital, Kigali, Rwanda, erudakemwa@gmail.com. 7. Centre Hospitalier Universitaire de Kigali (CHUK), Rwanda, ndacyayisengav@gmail.com. 8. RASD, Kigali Rwanda, dusingize@gmail.com. 9. Department of Physiotherapy, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand; aimee.stewart@wits.ac.za. 10. Deputy Executive Director, Witwatersrand Reproductive Health and HIV Institute (WRHI), Associate Professor, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa, fventer@wrhi.ac.za. 11. Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY USA, kathryn.anastos@gmail.com.
Abstract
BACKGROUND: Peripheral neuropathy symptoms (PNS) are commonly manifested in HIV-infected (HIV+) individuals, although data are limited on the prevalence and predictors of PNS in HIV+ patients from sub-Saharan Africa. OBJECTIVE: To determine the prevalence and predictors of PNS in HIV+ and HIV-uninfected (HIV-) Rwandan women. METHODS: Data were analysed from 936 (710 HIV+ and 226 HIV-) women from the Rwanda Women Interassociation Study and Assessment (RWISA), an observational prospective cohort study investigating the effectiveness and toxicity of ART in HIV+ women. RESULTS: Of 936 enrolled, 920 (98.3%) were included in this analysis with 44% of HIV- and 52% of the HIV+ women reporting PNS (p=0.06). CD4+ count was not associated with PNS, although there was a non-significant trend towards higher prevalence in those with lower CD4+ counts. For the HIV- women, only alcohol and co-trimoxazole use were independently associated with PNS. WHO HIV stage IV illness and albumin ≤ 3.5 were associated with PNS in HIV+ women. CONCLUSIONS: The rate of peripheral neuropathy symptoms reported in this cohort of HIV-infected African women seems implausible, and rather suggests that the screening tool for peripheral neuropathy in culturally diverse African settings be locally validated.
BACKGROUND:Peripheral neuropathy symptoms (PNS) are commonly manifested in HIV-infected (HIV+) individuals, although data are limited on the prevalence and predictors of PNS in HIV+ patients from sub-Saharan Africa. OBJECTIVE: To determine the prevalence and predictors of PNS in HIV+ and HIV-uninfected (HIV-) Rwandan women. METHODS: Data were analysed from 936 (710 HIV+ and 226 HIV-) women from the Rwanda Women Interassociation Study and Assessment (RWISA), an observational prospective cohort study investigating the effectiveness and toxicity of ART in HIV+ women. RESULTS: Of 936 enrolled, 920 (98.3%) were included in this analysis with 44% of HIV- and 52% of the HIV+ women reporting PNS (p=0.06). CD4+ count was not associated with PNS, although there was a non-significant trend towards higher prevalence in those with lower CD4+ counts. For the HIV- women, only alcohol and co-trimoxazole use were independently associated with PNS. WHO HIV stage IV illness and albumin ≤ 3.5 were associated with PNS in HIV+ women. CONCLUSIONS: The rate of peripheral neuropathy symptoms reported in this cohort of HIV-infected African women seems implausible, and rather suggests that the screening tool for peripheral neuropathy in culturally diverse African settings be locally validated.
Entities:
Keywords:
HIV and Rwandan women; Peripheral neuropathy symptoms
Authors: David M Simpson; Anna-Bettina Haidich; Giovanni Schifitto; Constantin T Yiannoutsos; Anthony P Geraci; Justin C McArthur; David A Katzenstein Journal: AIDS Date: 2002-02-15 Impact factor: 4.177
Authors: Mark Kaddumukasa; Leviticus Mugenyi; Martin N Kaddumukasa; Edward Ddumba; Michael Devereaux; Anthony Furlan; Martha Sajatovic; Elly Katabira Journal: BMC Neurol Date: 2016-11-17 Impact factor: 2.474
Authors: Frank Ndaks Ndakala; Julius Otieno Oyugi; Margaret Ng'wono Oluka; Joshua Kimani; Alexandra Jablonka; Georg Martin Norbert Behrens Journal: Pan Afr Med J Date: 2016-09-20
Authors: Peter Puplampu; Vincent Ganu; Ernest Kenu; William Kudzi; Patrick Adjei; Leticia Grize; Michael Käser Journal: J Neurovirol Date: 2019-04-26 Impact factor: 2.643
Authors: Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Ronald H Gray; Maria J Wawer; Ned Sacktor Journal: Neurology Date: 2017-07-05 Impact factor: 9.910